Importantly, our recent study provided additional in loco evidence for the anti‐inflammatory effects of rivaroxaban, demonstrating decreased NF‐κB expression and lower IL‐6 fluorescence intensity within stenotic leaflets from AS patients receiving rivaroxaban compared with non‐DOAC users [21]. This evidence concerns the gene NFKB1 and aortic stenosis.